Ironwood price target lowered to $11.50 from $12.50 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Ironwood Pharmaceuticals to $11.50 and reiterates a Sell rating on the shares. The company’s “poor” recent financial performance is unlikely to improve in the near-term, Selvaraju tells investors in a research note. He expects Linzess pricing decreases and challenges to uptake will continue.
https://thefly.com/landingPageNews.php?id=2834345